Heike Cappel-Porter

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Objectives IVAN and TANDEM are factorial randomised controlled trials (RCTs) of different treatment regimens for wet AMD, involving off-label use of bevacizumab. Safety data are being collected but, given follow-up visits every 4-8 weeks for up to 3 years and verbatim reporting, are difficult to collate. We have developed a database solution for the TANDEM(More)
  • 1